Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

CMS Issues Proposed Coverage Decision for Renal Denervation

News Daily News

CMS Issues Proposed Coverage Decision for Renal Denervation

July 11, 2025

TCTMD’s Top 10 Most Popular Stories for January 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2025

January 31, 2025

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

News Conference News ESC 2024

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

Yael L. Maxwell

September 04, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

News Daily News

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

November 20, 2023

FDA Approves Paradise Renal Denervation System: What Comes Next?

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

November 08, 2023

What’s Going to Be Hot at AHA 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

November 07, 2023

Sham Procedures in CV Research: What’s Sacrificed for Science?

News Daily News

Sham Procedures in CV Research: What’s Sacrificed for Science?

October 23, 2023

European Societies Define Best Practices for Performing Renal Denervation

News Daily News

European Societies Define Best Practices for Performing Renal Denervation

February 21, 2023

Reduction in BP Drives Treatment Preference for Hypertensive Patients

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

TCTMD’s Top 10 Most Popular Stories for July 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2022

August 01, 2022

Renal Denervation a Third Option for Hypertension, European Experts Say

News Daily News

Renal Denervation a Third Option for Hypertension, European Experts Say

September 17, 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

TCTMD’s Top 10 Most Popular Stories for May 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2019

May 31, 2019

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

Patient Perspectives on Sham-Controlled Trials

Presentation TCT 2018

Patient Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Debbe McCall

September 23, 2018

FDA Perspectives on Sham-Controlled Trials

Presentation TCT 2018

FDA Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Hiren Mistry

September 23, 2018

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

Presentation TCT 2018

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, David E. Kandzari

September 23, 2018

ORBITA One Year Later: What Would I Do Differently, If Anything?

Presentation TCT 2018

ORBITA One Year Later: What Would I Do Differently, If Anything?

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Rasha Al-Lamee

September 23, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.